IDF21-0036 Patient-Reported Outcomes in Patients with Type 2 Diabetes Treated with Tirzepatide or Insulin Degludec (SURPASS-3). (April 2022) - Yu, M.; Bray, R.; Brown, K.; Fernández Landó, L.; Rodríguez, Á.; Boye, K.